Putting 28.7% Weight Loss in Context: What Retatrutide's Numbers Mean

Beyond the Headline Number

Retatrutide’s Phase 2 trial reported a mean body weight reduction of 24.2% at 48 weeks in the 12 mg dose group. That figure has now been beaten. TRIUMPH-4, the first Phase 3 result (December 2025), showed 28.7% mean weight loss at 12 mg over 68 weeks in 445 participants with obesity and knee osteoarthritis. The 9 mg group reached 26.4%, versus 2.1% on placebo. To understand what these numbers mean for an individual, and how they compare with other treatments, you need more context than the percentages give on their own.

What 28.7% Looks Like in Absolute Terms

For a person who starts at 250 pounds (113 kg), a 28.7% reduction means losing about 72 pounds (33 kg), ending up around 178 pounds. For someone starting at 300 pounds (136 kg), it would mean losing roughly 86 pounds (39 kg) and reaching about 214 pounds.

These are big changes with real clinical consequences. Weight loss on this scale is linked to improvement or resolution of many obesity-related conditions, including type 2 diabetes, hypertension, obstructive sleep apnea and osteoarthritis. It passes the thresholds that many clinical guidelines tie to significant cardiometabolic benefit.

Comparison to Other Interventions

Here is where 28.7% weight loss sits among the treatments available:

• Lifestyle intervention alone (diet, exercise, behavioral counseling) usually produces 3-7% weight loss at one year, and most people regain much of it afterwards.
• Older drugs such as orlistat produce modest reductions of about 3-5% beyond placebo.
• Semaglutide 2.4 mg (Wegovy) showed about 15% mean weight loss at 68 weeks in the STEP 1 trial.
• Tirzepatide (Zepbound) produced up to 22.5% mean weight loss at 72 weeks in the SURMOUNT-1 trial.
• Bariatric surgery: Roux-en-Y gastric bypass usually produces 25-35% total body weight loss at one to two years, while sleeve gastrectomy produces 20-25%.

Retatrutide’s Phase 3 results put a drug squarely in the range of surgery. At 28.7%, the 12 mg dose is above the typical range for sleeve gastrectomy and overlaps the middle of the gastric bypass range. This is a historic threshold, now confirmed in a Phase 3 trial with 445 participants over 68 weeks.

The Importance of Responder Analysis

Average weight loss figures are useful, but they can hide how individual results are spread. Responder analyses from the retatrutide Phase 2 trial help here. In the 12 mg group, about 93% lost at least 10% of their body weight, and about 83% lost at least 15%. A notable share lost more than 25%.

This spread matters clinically because it suggests most patients, not just a few exceptional responders, can expect substantial benefit. It also means some patients will respond less strongly. Working out what predicts response and non-response is an important area of ongoing research.

Clinical Thresholds That Matter

Regulators and clinicians often use set weight loss thresholds to judge treatment benefit:

• ≥ 5%: The minimum most guidelines consider clinically meaningful, linked to better blood sugar control and cardiovascular risk factors.
• ≥ 10%: Linked to significant improvements in obstructive sleep apnea, MASLD and quality of life.
• ≥ 15%: Increasingly linked to changing the course of type 2 diabetes, including possible remission.
• ≥ 20%: Approaches results once possible only with surgery, with matching benefits for mobility, joint health and psychological and social well-being.

Retatrutide’s average effect at the highest dose now approaches the 30% mark in Phase 3 data, well beyond the 20% level once thought reachable only with surgery.

Weight Loss Is Not the Whole Story

The amount of weight lost is the outcome people quote most, but the real clinical value of any obesity treatment depends on its effects on hard endpoints (cardiovascular events, death, quality of life) and on its long-term safety and tolerability. Phase 3 trials and post-marketing surveillance will show whether retatrutide’s impressive weight loss leads to equally large clinical benefit over time.

The data so far are encouraging. But percentage points on a graph eventually have to be backed up by the outcomes that matter most to people living with obesity.